A recent study reveals representative data about how next-generation sequencing (NGS) tests are practically used by oncologists in the United States to evaluate cancer patients and how these technologies guide cancer treatment recommendations. It indicates that 75.6% of oncologists would choose NGS tests to guide treatment decisions, 34.0% of which are applied for treatment guidance of patients with advanced refractory disease, 29.1% for clinical trial eligibility, and 17.5% for off-label use of FDA-approved drugs.
More and more data is showing that genetic analysis gives researchers a chance to apply knowledge in practice, especially in the early disease detection and diagnosis of genetic disorders. This significantly improves medical care for many because it can not only assess disease risk and inform disease-management strategies for individuals but also foreshadow possible risks for family members.
By creating faster, newer, and more affordable ways to understand genomic samples, next-generation sequencing technologies are progressively playing an important role in cancer research. NGS tests help enable early detection and interception of tumor development, meanwhile contributing to developing potential target therapies and building knowledge around tumor evolution.
Cancer Sequencing Technologies in Precision Oncology
Biomarker testing for cancer treatment is widely used to look for specific genes, proteins, and other substances that can provide information about cancer. These tumor markers can guide treatment decisions for a specific type of cancer and monitor cancer during and after treatment, which is known as precision oncology.
85% of the disease-causing variants in cancer are estimated to locate in coding and functional regions of the genome. Therefore, sequencing of the complete coding regions (exome) may indicate the causes of several rare, mostly monogenic, genetic disorders as well as predisposing variants in common diseases and cancers. Whole-exome sequencing (WES) is one of the major NGS technologies widely used in cancer sequencing. It exerts great influence in cancer research due to its ability to gather and bank an entire exome for analysis and future reference. Using whole-exome sequencing for biomarkers discovery, genetic mutation identification, and detecting other gene changes has helped researchers understand cancer growth drivers and expanded the knowledge base in cancer investigation.
Another important cancer sequencing technology is RNA sequencing. As the central dogma suggests, DNA contains the required information for making functional products—proteins. And RNA carries the necessary information to the ribosomes so that ribosomes can translate and convert the information into functional proteins, which is known as gene expression. Therefore, researchers can sequence the RNA in cells to understand the transcriptional regulation as well as to detect splice variants, fusions, and other mutations arising in the transcriptional process. These RNA modifications give researchers more information about understanding the complexity of cancer and other diseases.
Next-Generation Sequencing Market
Increasing demand for innovative technologies featured with both short and large genomic reads, faster speeds, and higher accuracy, is driving the growth of sequencing platforms. And the global next-generation cancer diagnostics market is expected to grow to $16.7 billion by 2025 according to a recent report. Biotech companies are scrambling to develop low-cost while efficient sequencing platforms, for example, the SuPrecision™ platform by Creative Biolabs. Generally speaking, the pivotal role of sequencing technologies in cancer research drives continuous advancements in the NGS market.
The global Next Generation Sequencing Market report offers a comprehensive assessment of the market for the forecast years.
The report contains several segments and an analysis of the market trends and growth factors that are playing a vital role in the market.
This global industry offers an outlook on the strategic development of the market in terms of revenue profits over the forecast period 2021-2030.The leading companies in Global Next Generation Sequencing Market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile, and STD Reimbursement Scenario Analysis, and Top Study Testing Technologies products and services.The key market players for the global Next Generation Sequencing Market are listed below:Agilent Technologies, IncBGI Group F. Hoffmann-La Roche AG Illumina IncPrecigen Inc., (Intrexon Bioinformatics Germany GmbH)Pacific Biosciences of California, IncPerkinElmer, Inc.PierianDx Inc.Qiagen N.V.Thermo Fisher Scientific Inc.(A PDF | Sample Of The Report Is Available Immediately Upon Request) @ https://www.alliedmarketresearch.com/request-sample/2048 The Global Next Generation Sequencing Market Report is equipped with market data from 2021 to 2030.
It also evaluates the competitive scenario of the leading players.
The detailed sales channel is also covered in the study.Covid-19 Scenario:1) The Covid-19 pandemic and followed by lockdown has affected several manufacturing industries.2) The prolonged lockdown resulted in a disrupted supply chain and increased the prices of raw materials.3) However, as the world has been recovering from the pandemic, the market is estimated to get back on track.Detailed COVID-19 Impact Analysis on Market: https://www.alliedmarketresearch.com/request-for-customization/2048?reqfor=covid Why Purchase this Report?A robust research methodology has been followed to collect data for the report.
Data, thus collected passes through multiple quality checks to ensure the best quality is served.The report gives a holistic view of the competitive scenario of the Next Generation Sequencing Market.The latest product launches along with technological changes and development are covered in the report.The data analysis in the report helps in understanding the anticipated Next Generation Sequencing Market dynamics from 2021 to 2030.Decision Databases has a vast repository of data, therefore, we can accommodate customized requirements also.The graphs, tables and pie charts, and info-graphics covered in the report will help in a better understanding of the report.The market drivers, restraints, upcoming opportunities, and anticipated restraints cited in the report will assist in making an informed decision.Interested in Procuring this Report?
The global next generation sequencing market is expected to reach USD 19.70 billion by 2025 registering a CAGR of 12.78%, according to a new report by Grand View Research, Inc.
Growing application of NGS methodologies due to rising number of strategic developments initiated by the market participants is one of the key drivers of the market.
These novel strategies mark the presence of intense competition between the key firms.
Companies are further increasing their installation base by providing sequencing services in different emerging countries.
For instance, in April 2018, Illumina entered into a partnership with Loxo Oncology for the development of Illumina TruSight Tumor 170 NGS test as a companion diagnostic for Loxo Oncology’s LOXO-292 and larotrectinib for tumor profiling.Similarly, in March 2018, PierianDx partnered with cancer genetics to offer NGS-based tests for oncology precision medicine.
NGS technologies experience significant growth due to rapid automation in the pre-sequencing protocols and advancements in clinical diagnosis and disease testing.
Next Generation Sequencing Market Research Report: By Technology (Targeted Sequencing & Resequencing, Whole Genome Sequencing and Whole Exome Sequencing), Workflow (Pre-Sequencing, Sequencing, and Data Analysis), Application (Oncology, Clinical Investigation, Reproductive Health, Human Leukocyte Antigen Typing or Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics), End User (Hospitals & Clinics, Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Global Forecast till 2025Global Next Generation Sequencing Market Share is expected to exhibit significant growth over the forecast period.
The NGS Market Growth is projected to register a CAGR of 18.05% over the forecast period to reach USD 20,347.45 Million by 2025.There are various diseases that have their roots in genetics such as cancer, diabetes, Alzheimer’s, arthritis, heart disease etc.
To discover viable treatment to these diseases, researchers are looking to discern how genes work.
Next generation sequencing market has been gaining impetus due to the fact that next-generation sequencing is integral to field of genomics.
The NGS technologies are implemented for several applications, including whole genome sequencing, de novo assembly sequencing, resequencing, and transcriptome sequencing at the DNA or RNA level.
The successful application of next-generation sequencing can lead to predicting of genes, protein coding regions, and pathways.Illumina, Helicos Biosciences, Thermo Fisher Scientific, Roche, Pacific Bioscience, ABI Life Technologies, and Oxford Nanopore are some of the companies that are implementing different NGS technologies which in turn will augment global next generation sequencing market which is estimated to reach a massive market valuation by 2023.Next Generation Sequencing Market Competitive Landscape:Some of the key players in the global next-generation sequencing market Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., BGI, PerkinElmer, Agilent Technologies, QIAGEN N. V., Macrogen Inc., Oxford Nanopore Technologies, Ltd., and Eurofins Scientific.
